Unit:
Κατεύθυνση Οικονομία και Διοίκηση Υπηρεσιών ΥγείαςLibrary of the Faculty of Economics and of the Faculty of Business Administration
Author:
Mayrogiannis Gerasimos
Supervisors info:
Ιωάννης Υφαντόπουλος, Oμότιμος Καθηγητής, Τμήμα Πολιτικής Επιστήμης και Δημόσιας Διοίκησης, ΕΚΠΑ
Original Title:
Ανάλυση κόστους αποτελεσματικότητας: καρκίνος του πνεύμονα στην Ελλάδα
Translated title:
Cost-effectiveness analysis: lung cancer in Greece
Summary:
Τhis work consists of two parts, a theoretical overview and an empirical one through which we have achieved concrete results and conclusions. Lung cancer, and more specifically Non-squamous Non-Small Cell Lung Cancer is the most frequently occurring lung cancer and is associated with significant mortality. According to the clinical study Checkmate 057, Nivolumab demonstrated an improvement in the overall survival of OS patients with advanced / metastatic Non-squamous Non-Microvascular Lung Cancer following chemotherapy. Nivolumab has recently been approved in several countries, including Greece. NICE recommends the use of Nivolumab for Non-Plaque Non-Small Cell Lung Cancer under certain conditions. The purpose of this analysis is to evaluate the cost and efficacy of Nivolumab compared to Docetaxel as a second line of treatment in patients with advanced / metastatic Non-squamous Non-Small Cell Lung Cancer in Greece from the perspective of the National Health System. The Markov model was used in the analysis. The survival model consists of three health states, no progression of PFS disease, progression of PD disease and death. The population of interest was 62 years of age with advanced / metastatic Non-squamous Non-Microvascular Lung Cancer who had previously received chemotherapy. The data and data we used in this study were derived from Greek and international literature.
The model followed a hypothetical group of patients from the beginning of treatment to death with one-month cycles. Data and probabilities for PFS and OS were derived from the clinical study (Checkmate 057), and the results for a sixty-month lifetime lifetime lifetime coverage of these patients were generalized. The clinical outcome was associated with the quality of life and the cost was estimated by combining use of resources and unit price according to state compensation rates. Cost and effectiveness were calculated per patient, in each health state for each cycle of the model.
Main subject category:
Health Sciences
Keywords:
Non squamous NSCLC, economic evaluation, cost effectiveness, ICER, Nivolumab, Docetaxel,Health Technology assessment
